Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL67926 | 0.85 | MAPK1 (1.00) | MAPK1P2RX7 | |
| SCHEMBL23876033 | 0.84 | MAPK1 (0.50) | MAPK1P2RX7 | |
| Dioxane SCHEMBL1995894 | 0.82 | MAPK1 (0.93) | MAPK1P2RX7 | |
| SCHEMBL1995890 | 0.78 | MAPK1 (0.84) | MAPK1P2RX7 | |
| SCHEMBL14782402 | 0.77 | P2RX7 (0.65) | MAPK1P2RX7 | |
| SCHEMBL16679197 | 0.76 | MAPK1 (0.79) | MAPK1P2RX7 | |
| SCHEMBL22548973 | 0.76 | MAPK1 (0.73) | MAPK1P2RX7 | |
| SCHEMBL23755678 | 0.76 | MAPK1 (0.80) | MAPK1P2RX7 | |
| SCHEMBL25709689 | 0.74 | MAPK1 (0.40) | MAPK1P2RX7 | |
| SCHEMBL21238580 | 0.74 | P2RX7 (0.41) | MAPK1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| EP-3865484-B1 | PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H LUNDBECK AS (DK) | 2023-11-08 | — | — | EP | disclosed |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| US-11382949-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-03-31 | — | — | US | disclosed |
| US-20210300904-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-09-30 | — | — | US | disclosed |
| EP-3865484-A1 | PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. Lundbeck A/S (DK) | 2021-08-18 | — | — | EP | disclosed |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3303339-B1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H LUNDBECK AS (DK) | 2021-01-13 | — | — | EP | disclosed |
| US-20200354408-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-11-12 | — | — | US | disclosed |
| US-10793604-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190307838-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-10-10 | — | — | US | disclosed |
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-15 | — | — | US | disclosed |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | MAPK1 1689/4885P2RX7 1832/4885 |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | MAPK1 2736/4885P2RX7 843/4885 |
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MAPK1 541/4885P2RX7 3341/4885 |
| US-11382949-B2 | Anthelmintic depsipeptide compounds | ENPP2, ROCK2, RRP12 | MAPK1 1749/4885P2RX7 395/4885 |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | MAPK1 541/4885P2RX7 3341/4885 |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MAPK1 541/4885P2RX7 3341/4885 |
| US-10793604-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | MAPK1 3054/4885P2RX7 286/4885 |
| US-20210300904-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | MAPK1 268/4885P2RX7 3369/4885 |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MAPK1 541/4885P2RX7 3341/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MAPK1 541/4885P2RX7 3341/4885 |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | MAPK1 2977/4885P2RX7 243/4885 |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | MAPK1 541/4885P2RX7 3341/4885 |
| US-20190307838-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | ENPP2, ROCK2, RRP12 | MAPK1 1749/4885P2RX7 395/4885 |
| US-20200354408-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | MAPK1 3054/4885P2RX7 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.